Related Experiment Video
Updated: Dec 26, 2025
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
Nimustine Treatment of 11 Cases of Canine Histiocytic Sarcoma
Hiroyuki Tani1, Sena Kurita1, Ryo Miyamoto1
1From the Department of Veterinary Clinical Pathology (H.T., S.K., R.M., K.T., M.B.), Veterinary Medical Teaching Hospital (H.S.), Laboratory of Veterinary Radiology (A.F.-I., D.H.), Department of Veterinary Pathology (M.M.), and Department of Veterinary Nursing (D.A.), Nippon Veterinary and Life Science University, Tokyo, Japan.
Abstract:
The objective of this retrospective study was to report treatment outcomes in dogs with histiocytic sarcoma (HS) that were treated with nimustine (ACNU). This study evaluated data from 11 dogs including 5 with macroscopic tumors that were treated in the primary setting and 6 that underwent aggressive local therapy while being treated in the adjuvant setting. The median ACNU starting dose was 25 mg/m
